Celltrion Launches Yuflyma (biosimilar, adalimumab) for the Treatment of Multiple Chronic Inflammatory Disease in Canada
Shots:
- The company reported the commercial availability of Yuflyma in Canada as a new treatment option for physicians & patients. Yuflyma is the high-concentration (100 mg/mL), low-volume & citrate-free biosimilar of its biosimilar referencing Humira across Canada to treat multiple CID
- Yuflyma is a recombinant human mAb that contains the active ingredient adalimumab which is a fully human anti-TNFα mAb & is available in 2 device types i.e., auto-injector and pre-filled syringe with safety guard
- The company has also launched a patient support program, Celltrion Connect to support patients & healthcare providers along with guidance with reimbursement navigation, financial assistance, inj., nurse support services & pharmacy support services for patients during treatment
Ref: Newswire | Image: Celltrion
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
